Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

Stopped early · Phase 2

Conditions studied: Eosinophilia, Hypereosinophilic Syndrome

In brief

The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.

Key facts

Study ID

NCT00230334

Run by

Steven E. Coutre

People needed

5

Starts

2003-06-12

Expected to finish

2007-05-01

Last updated by the study team

2021-05-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.